The company initially plans to launch the generic version in Canada, India, Brazil, Turkey and other emerging markets, subject to patent expiry, Israeli said at a press conference
The sales of Novo Nordisk's Rybelsus tablet, used for diabetes treatment and weight reduction, more than doubled to Rs 363 crore this year from Rs 147 crore last year
